Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 12/20 | 0.37 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451783 | 1.00 | USP25 (0.43) | USP25USP28HDAC1PRKCQCCR2 | |
| SCHEMBL2458801 | 1.00 | USP25 (0.43) | USP25USP28HDAC1PRKCQCCR2 | |
| SCHEMBL2460684 | 0.95 | USP25 (0.39) | USP25USP28HDAC1PRKCQCCR2 | |
| SCHEMBL2462788 | 0.95 | USP25 (0.39) | USP25USP28HDAC1PRKCQCCR2 | |
| SCHEMBL2459768 | 0.90 | MAPT (0.41) | USP25USP28HDAC1CCR2IP6K1 | |
| SCHEMBL2463515 | 0.90 | MAPT (0.41) | USP25USP28HDAC1CCR2IP6K1 | |
| SCHEMBL2459776 | 0.90 | MAPT (0.41) | USP25USP28HDAC1CCR2IP6K1 | |
| SCHEMBL2461995 | 0.87 | ADRB1 (0.38) | USP25USP28CCR2IP6K1P2RX7 | |
| SCHEMBL2459779 | 0.86 | IP6K1 (0.40) | CCR2IP6K1P2RX7 | |
| SCHEMBL2458975 | 0.83 | IP6K1 (0.38) | CCR2IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | USP25 3089/4885USP28 2997/4885HDAC1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.